Johnson & Johnson

J&J-backed Cellular Origins raises $40M for cell therapy manufacturing

2 days ago talkbio0Tagged cell therapy manufacturing, Cellular Origins, Constellation platform, cyclic adenosine-5'-trimetaphosphate, Groups, Johnson & Johnson, Manufacturing, Purpura, Thrombotic Thrombocytopenic, robotic automation

Cellular Origins; Johnson & Johnson; Series A; $40 million; cell therapy manufacturing; Constellation platform; robotic automation; ATMP; TTP Group; scalable manufacturing

Johnson & Johnson Halts Phase 2 Alzheimer’s Trial After Tau Antibody Failure

3 weeks ago talkbio0Tagged Alzheimer 's disease, Clinical Failure, Clinical Trials, discontinued, Johnson & Johnson, posdinemab, tau-targeting antibody

Johnson & Johnson; Alzheimer’s disease; tau-targeting antibody; posdinemab; Phase 2b AuTonomy trial; clinical failure; trial discontinued

Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion to Add RIPTAC Cancer Drug Platform

4 weeks ago talkbio0Tagged Acquisition, clinical pipeline, Halda Therapeutics, HLD-0915, Johnson & Johnson, Malignant neoplasm of prostate, Neoplasms, RIPTAC, Targeted Protein Degradation

Johnson & Johnson; Halda Therapeutics; acquisition; RIPTAC; HLD-0915; prostate cancer; targeted protein degradation; oncology; clinical pipeline

Pharma Investment Surge in US Manufacturing Creates Major Opportunities for CDMOs

1 month ago talkbio0Tagged Advanced therapies, alpha 1-antitrypsin, Biological Factors, capital investment, CDMOs, eli lilly, Growth, Johnson & Johnson, Market, pharmaceutical manufacturing, production, supply chain, U.S.

US pharmaceutical manufacturing; CDMOs; capital investment; Johnson & Johnson; Eli Lilly; biologics; API production; supply chain; advanced therapies; market growth

Inspira Technologies Appoints Former Johnson & Johnson Executive as VP of Global Sales

2 months ago talkbio0Tagged Appointments, Arginine Vasopressin-Neurophysin II Preproprotein, board of directors, commercialization, global sales, Health care facility, Inspira Technologies, Johnson & Johnson, Leadership, Mike Hershkovitz

Inspira Technologies; Mike Hershkovitz; Johnson & Johnson; VP of Global Sales; leadership appointment; healthcare; commercialization; board of directors

Johnson & Johnson to Separate Orthopaedics Business

2 months ago talkbio0Tagged DePuy Synthes, Diastasis, Johnson & Johnson, medtech, Orthopedics

Johnson & Johnson; Orthopaedics; DePuy Synthes; MedTech; Separation

FDA Issues Warning Letter to J&J Subsidiary Over Stopper Issues and Quality Reporting at Korean Plant

3 months ago talkbio0Tagged Cautionary Warning, Incheon, Janssen Vaccines, Johnson & Johnson, Korean language, pharmaceutical manufacturing, Plants, production, quality control violations, spotty complaint reporting, United States Food and Drug Administration, vial stopper defects

FDA warning letter; Johnson & Johnson subsidiary; Janssen Vaccines; Korean production plant; vial stopper defects; quality control violations; spotty complaint reporting; good manufacturing practices; Incheon; pharmaceutical manufacturing

J&J’s Oral IL-23 Drug Icotrokinra Surpasses Sotyktu in Phase 3 Psoriasis Trials

3 months ago talkbio0Tagged Dental Plaque, deucravacitinib, IL-23 receptor antagonist, JNJ-2113, Johnson & Johnson, Myers, oral peptide, Phase 3 clinical trial, Psoriasis, skin clearance, Sotyktu

Icotrokinra; JNJ-2113; Johnson & Johnson; IL-23 receptor antagonist; Sotyktu; deucravacitinib; plaque psoriasis; Phase 3 clinical trial; skin clearance; oral peptide; Bristol Myers Squibb

J&J’s Inlexzo Bladder Cancer Therapy Wins ‘Practice-Changing’ FDA Approval

3 months ago talkbio0Tagged Approved, BCG-Unresponsive, Carcinoma, Drug Delivery Systems, gemcitabine intravesical system, in situ, Inlexzo, Johnson & Johnson, Malignant neoplasm of urinary bladder, New, Non-Muscle Invasive Bladder Neoplasms, SunRISe-1 trial, United States Food and Drug Administration

Inlexzo; FDA approval; bladder cancer; Johnson & Johnson; gemcitabine intravesical system; BCG-unresponsive; non-muscle invasive bladder cancer; SunRISe-1 trial; novel drug delivery; carcinoma in situ

AstraZeneca Escalates EGFR Lung Cancer Rivalry with J&J: Tagrisso Combo Posts Survival Win

3 months ago talkbio0Tagged AstraZeneca, Combined, EGFR-mutated, FLAURA2 trial, Johnson & Johnson, Lazcluze, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Overall Survival, Pharmacotherapy, Rybrevant, Tagrisso

AstraZeneca; Tagrisso; EGFR-mutated NSCLC; Johnson & Johnson; Rybrevant; Lazcluze; Flaura2 trial; overall survival; lung cancer; chemotherapy combination